| 1.96 -0.28 (-12.5%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.43 |
1-year : | 2.84 |
| Resists | First : | 2.08 |
Second : | 2.44 |
| Pivot price | 1.8  |
|||
| Supports | First : | 1.5 |
Second : | 1.24 |
| MAs | MA(5) : | 2.14 |
MA(20) : | 1.82 |
| MA(100) : | 2.54 |
MA(250) : | 6.08 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 68.3 |
D(3) : | 78.4 |
| RSI | RSI(14): 49.1 |
|||
| 52-week | High : | 12.22 | Low : | 1.5 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ TPST ] has closed below upper band by 36.1%. Bollinger Bands are 37.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.28 - 2.29 | 2.29 - 2.3 |
| Low: | 1.81 - 1.82 | 1.82 - 1.83 |
| Close: | 1.94 - 1.96 | 1.96 - 1.97 |
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
Fri, 17 Apr 2026
TPST Forecast, Price Target & Analyst Ratings | TEMPEST THERAPEUTICS INC (NASDAQ:TPST) - ChartMill
Fri, 10 Apr 2026
Tempest Therapeutics (NASDAQ: TPST) registers 2.78M resale shares from private placement - Stock Titan
Fri, 10 Apr 2026
Tempest Therapeutics (NASDAQ: TPST) registers 8.27M shares for resale by sellers - Stock Titan
Fri, 10 Apr 2026
[EFFECT] Tempest Therapeutics, Inc. SEC Filing - Stock Titan
Thu, 02 Apr 2026
Tempest Therapeutics (TPST) grants 22,000 stock options to Corporate Controller - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 13 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 37.1 (%) |
| Held by Institutions | 5.7 (%) |
| Shares Short | 132 (K) |
| Shares Short P.Month | 193 (K) |
| EPS | -9.73 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.42 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -89.4 % |
| Return on Equity (ttm) | -405.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.69 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -33 (M) |
| Levered Free Cash Flow | -20 (M) |
| PE Ratio | -0.21 |
| PEG Ratio | 0 |
| Price to Book value | 1.37 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.8 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|